Expression of CD44 variant 9 in rectal cancer after treatment of neoadjuvant chemotradiotherapy
| Project/Area Number |
26462004
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
OHKOHCHI Nobuhiro 筑波大学, 医学医療系, 教授 (40213673)
ODA Tatsuya 筑波大学, 医学医療系, 教授 (20282353)
MURATA Soichiro 横浜市立大学, 大学院医学研究科, 准教授 (40436275)
TAKEUCHI Tomoyo 筑波大学, 医学医療系, 助教 (50450333)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 直腸癌 / 術前化学放射線療法 / CD44variant 9 / 癌幹細胞 / 大腸癌 / 新規診断法 / CD44v9 / 直腸癌局所再発 |
|---|
| Outline of Final Research Achievements |
Introduction: CD44 variant 9 is important factor of cancer stem cell in colorectal cancer, however, its clinical role is uncertain.Aims: Objective of this study is to evaluate the immune-histochemical expression of CD44 variant 9 as stem cell marker in the colorectal cancer after treatment of neoadjuvant chemoradiotherapy (NCRT). Material and Methods: This study included 20 rectal specimens. All specimens were underwent NCRT. Clinical data were available for all case.Result: Average score of Expression of CD44 after NCRT is 0.93 (0-2.4). Expression score of CD44 variant 9 is in proportion to efficacy of pathological grade; grade2/ 1a/ 0 is 0.3/1.6/2, respectively. However, Expression score of relapse patient, non-relapse patient is 0.8 and 0.93, respectively. The correlation between relapse of tumor and expression of CD44 variant 9 is not significant.Conclusion: Expression of CD44 variant 9 might be associated with treatment effect of NCRT, however, no relation to prognosis.
|
Report
(4 results)
Research Products
(5 results)
